Clinical and pre-clinical data on compounds representing several of the largest diabetes treatment classes will be presented
INGELHEIM, Germany & INDIANAPOLIS, US -- (BUSINESS WIRE) --
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance portfolio June 5-9 at the American Diabetes Association’s® (ADA) 75th Scientific Sessions in Boston.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150527005742/en/
“With growing numbers of people being diagnosed with diabetes, there is tremendous need for ongoing clinical research to ensure treatment options and approaches are available to meet patients’ diverse needs,” said Professor Hans-J. Woerle, Vice President, Head of Medicine, Therapeutic Area Metabolism, Boehringer Ingelheim. “As part of our commitment to the diabetes community, the BI-Lilly diabetes alliance will present an array of product, disease state and patient-physician survey data that help address the needs of adults with diabetes.”
Highlighted presentations and posters include:
Empagliflozin/Metformin Data
Sunday, June 7, 2015: 12 p.m. – 2 p.m. EDT – General Poster Session
-
Initial Combinations of Empagliflozin and Metformin in Patients with Type 2 Diabetes
(Presenting Author: Hadjadj, S.) [119-LB]
Empagliflozin plus immediate-release metformin hydrochloride is being studied for the treatment of adults with type 2 diabetes (T2D). Data on this combination will be discussed in a late-breaker poster presentation.
IntroDia™ Survey Patient Data
Sunday, June 7, 2015: 12 p.m. – 2 p.m. EDT – General Poster Session
- Physician-Patient Communication At Prescription of an Additional Oral Agent for Type 2 Diabetes (T2D): Link Between Key Conversation Elements, Physician Empathy and Patient Outcomes - Insights From the Global IntroDia™ Study (Presenting Author: Capehorn, M.) [63-LB]
IntroDia™ is the largest global patient and physician survey ever conducted that focuses on early conversations about T2D – providing insights into how physicians and patients interact at important moments of the diabetes treatment journey. New results from the survey will be presented as a late-breaker poster presentation.
Trajenta® (linagliptin) Data
Sunday, June 7, 2015: 12 p.m. – 2 p.m. EDT – General Poster Session
- Safety and Efficacy of Linagliptin in Patients with Type 2 Diabetes (T2D) and Coronary Artery Disease (CAD): Analysis Of Pooled Incident Investigator Reported Events From Phase 3 Clinical Trials (Presenting Author: Leiter, L.) [1246-P]
Linagliptin (5mg, once-daily tablet), marketed as Trajenta® (linagliptin) in Europe and Tradjenta® (linagliptin) in the U.S., is a DPP-4 inhibitor, which works by increasing hormone levels that stimulate the pancreas to produce more insulin and the liver to produce less glucose. Data will be presented as a poster presentation.
A complete list of alliance abstracts to be presented or published at the ADA’s® Scientific Sessions can be found here.
Intended audiences
This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.
###
Please click on the link below for ‘Notes to Editors’ and ‘References’:
View source version on businesswire.com: http://www.businesswire.com/news/home/20150527005742/en/
CONTACT:
Dr Ralph Warsinsky
Corporate Communications
Boehringer Ingelheim GmbH
Email: ralph.warsinsky@boehringer-ingelheim.com
Phone: +49 (6132) 77-7051
or
Molly McCully
Communications Manager
Lilly Diabetes
Email: mccully_molly@lilly.com
Phone: +1 (317) 478 5423
